GLP-1 Oral Formulation Reaches 170K Prescriptions; Muscle Loss Concern at 40%

As of May 5, the newly approved GLP-1 oral formulation had been prescribed to 170K patients, surpassing the initial adoption pace of injectable versions. However, data showing up to 40% of weight loss originates from lean muscle, combined with widening 'Ozempic face' concerns, has triggered cycling behavior—users stopping and restarting treatment repeatedly.